28478-46-8

Usage

Uses

Used in Pharmaceutical Industry:
4-HYDROXY-2-METHOXY-BENZOIC ACID METHYL ESTER is used as a reagent for the synthesis of Ceralifimod, a sphingosine-1-phosphate receptor agonist. Ceralifimod is utilized in the treatment of autoimmune diseases, as it modulates the immune system and helps in managing the symptoms and progression of these conditions.

InChI:InChI=1/C9H10O4/c1-12-8-5-6(10)3-4-7(8)9(11)13-2/h3-5,10H,1-2H3

Upstream product

• 61539-61-5 1,1-dimethoxy-3-trimethylsilyloxy-1,3-butadiene 
• 922-67-8 propynoic acid methyl ester 
• 89-86-1 4-hydroxysalicylic acid 
• 124-41-4 sodium methylate 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 102127-34-4 4-bromo-3-methoxyphenol 
• 90111-34-5 4-hydroxy-2-methoxybenzoic acid 
• 18278-34-7 4-hydroxy-2-methoxybenzaldehyde 
• 136669-90-4 methyl 2-hydroxy-4-(trityloxy)benzoate 
• 5427-29-2 methyl 2-hydroxy-4-benzyloxybenzoate 
• 2150-47-2 methyl 2,4-dihydroxybenzoate 
• 845307-11-1 methyl 2-hydroxy-4-pivaloyloxybenzoate 
• 845307-13-3 methyl 2-methoxy-4-pivaloyloxybenzoate 

Downstream Products

• 95420-30-7 4-<(dimethylamino)thioxomethoxy>-2-methoxybenzoic acid methyl ester 
• 181269-73-8 methyl 5-fluoro-4-hydroxy-2-methoxybenzoate 
• 90111-34-5 4-hydroxy-2-methoxybenzoic acid 
• 202992-20-9 methyl 2-methoxy-4-{[(trifluoromethyl)sulfonyl]oxy}benzoate 
• 162045-37-6 4-(N-t-Butoxycarbonyl-4-piperidinyloxy)-2-methoxybenzoic acid methyl ester 
• 1131587-51-3 methyl 4-hydroxy-5-iodo-2-methoxybenzoate 
• 194151-75-2 methyl 4-(4-tetra-hydropyranoyloxy)-2-methoxy-benzoate 
• 1229688-83-8 methyl 4-(cis-2-phenyl-1-cyclohexanoyloxy)-2-methoxybenzoate 
• 136669-97-1 C-(2-Methoxy-4-methylsulfanyl-phenyl)-C-(4-methylsulfanyl-phenyl)-methylamine; compound with toluene-4-sulfonic acid 
• 136669-95-9 4-{2-[(9H-Fluoren-9-ylmethoxycarbonylamino)-(4-methanesulfinyl-phenyl)-methyl]-5-methanesulfinyl-phenoxy}-butyric acid 
• 136669-99-3 ({[(4-Methanesulfinyl-2-methoxy-phenyl)-(4-methanesulfinyl-phenyl)-methyl]-carbamoyl}-methyl)-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 136669-94-8 4-{2-[[(E)-Hydroxyimino]-(4-methylsulfanyl-phenyl)-methyl]-5-methylsulfanyl-phenoxy}-butyric acid 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR

This disclosure pertains to compounds, the preparation thereof, and the use of these compounds in the treatment of prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in subjects in need thereof.

SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING

A compound of formula (I), wherein: R1 is selected from (i) H, (ii) C3-6cycloalkyl, (iii) C3-7heterocyclyl optionally substituted with a group selected from: methyl and ester, and (iv) linear or branched C1-4alkyl optionally substituted with a group selected from: alkoxy, amino, amido, acylamido, acyloxy, alkyl carboxyl ester, alkyl carbamoyl, alkyl carbamoyl ester, phenyl, phosphonate ester, C3-7heterocyclyl optionally substituted with a group selected from methyl and oxo, and a naturally occurring amino acid, optionally N-substituted with a group selected from methyl, acetyl and boc; A1 is CRA or N; A2 is CRB or N; A3 is CRC or N; A4 is CRD or N; where no more than two of A1, A2, A3, and A4 may be N; one or two of RA, RB, RC, and RD, (if present) are selected from H, F, Cl, Br, Me, CF3, cyclopropyl, cyano, OMe, OEt, CH2OH, CH2OMe and CH2NMe2; the remainder of RA, RB, RC, and RD, (if present) are H; Y is O, NH or CH2; RY is selected from: (RYA) and (RYB).

Imidazole-containing condensed tricyclic compound and application thereof

The invention discloses an imidazole-containing condensed tricyclic compound adopting the structure as shown in the formula (I) or pharmaceutically acceptable salts, stereisomers or prodrug molecules thereof. The imidazole-containing condensed tricyclic compound has the IDO1 activity regulation function, can enhance T-cell activation through blocking immune checkpoints IDO1, is used for treating IDO1-mediated immunosuppression, and therefore, can become an effective medicine for treating malignant tumors. When used together with checkpoint protein anti-body drugs or other anti-cancer drugs, the imidazole-containing condensed tricyclic compound can enhance the anti-cancer effect. Meanwhile, the imidazole-containing condensed tricyclic compound has the potential of effectively treating IDO1 abnormity related immunosuppressive diseases and has a high application value.

NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

PHARMACEUTICAL COMPOUNDS

This invention relates to compounds that inhibit or modulate the activity of Chk-1 kinase. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.

Physiological activity of Chinese Lichen (Gyrophora esculenta) component, methyl 2,4-dihydroxy-6-methylbenzoate and the related compounds

It was confirmed that there was a higher expression of antioxidant potential in methyl 2,4-dihydroxy-6-methylbenzoate (orsellinic acid methyl ester) (2), which was isolated from methanol extract oil of Chinese lichen Gyrophora esculenta rather than from commercialized ascorbic acid. Taking this into account, 4 types of compounds-(4-7) which are known to be related to compound (2)-have been synthesized by using 2,4-dihydroxy benzoic acid (3) as starting material. After that, some physiological activity tests on these compounds have been conducted in the following aspects: antioxidant potential, cytotoxicity, cytokine suppressant effect and histamine liberation inhibition and the effects have been evaluated, respectively. The result shows that (2) and methyl 2,4-dihydroxybenzoate (4) showed high radical expression in both antioxidant potential and histamine liberation inhibition. It was also found that none of these compounds expresses cytotoxicity.

Piperidine-based heterocyclic oxalyl amides as potent p38α MAP kinase inhibitors

The design and synthesis of a new class of p38α MAP kinase inhibitors based on 4-fluorobenzylpiperidine heterocyclic oxalyl amides are described. Many of these compounds showed low-nanomolar activities in p38α enzymatic and cell-based cytokine TNFα produc

AMINO ALCOHOL DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USE OF THESE

The present invention provides compounds represented by general formula (I): a prodrug thereof, or pharmaceutical acceptable salts thereof, wherein R1 is hydrogen or lower alkyl; each of R2 and R3 is independently hydrogen or lower alkyl; each of R4, R5 and R6 is independently hydrogen, halogen, lower alkyl or lower alkoxy; R7 is hydrogen or lower alkyl; R8 is hydrogen, halogen, lower alkyl, lower alkoxy, etc; R9 is -COR10, -A1-COR10, -O-A2-COR10, etc; Ar is optionally substituted phenyl or heteroaryl; and A is a bond, -OCH2-, etc, which exhibit potent and selective β3-adrenoceptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.

AMINO ALCOHOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF

The present invention provides compounds represented by general formula (I): or pharmaceutical acceptable salts thereof, wherein R1 and R2 are each hydrogen or lower alkyl; R3 R4, R5 and R6 are each hydrogen, halogen, lower alkyl or lower alkoxy; R7 and R8 are each hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy, cycloalkyl, aryl, heteroaryl, cyano, a hydroxyl group, lower acyl, carboxy or the like; R9 is -C(O)-R10, -A1-C(O)-R10, -O-A2-C(O)-R10 or a tetrazol-5-yl group, which exhibit potent and selective β3-adrenoceptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.

Hydroxy-methoxybenzoic methyl esters: Synthesis and antifeedant activity on the pine weevil, Hylobius abietis

The pine weevil Hylobius abietis (L.) (Coleoptera: Curculionidae) feeds on the bark of coniferous seedlings and is the economically most important forestry restocking pest in large parts of Europe. Substances with an antifeedant effect may offer an environmentally friendly alternative to insecticides for the protection of planted seedlings. Bioassays were performed on commercial and synthetic methyl hydroxy-methoxybenzoates in order to determine their possible antifeedant activity. Two methyl hydroxy-methoxybenzoates were synthesized by esterification and mono-O-methylation of two dihydroxybenzoic acids. A regioselective protection-deprotection strategy was used in the synthetic pathway of the other non-commercial esters, esterification and selective pivaloylation of the less-hindered hydroxyl group of other commercial dihydroxybenzoic acids gave diester intermediates, which then were O-methylated before methanolysis of the pivaloyl group which yielded the desired non-commercial methyl hydroxy-methoxybenzoates. The five synthesized methyl hydroxy-methoxybenzoic esters were complemented with commercial samples of the five other isomers of methyl hydroxy-methoxybenzoate and spectrometric data were collected for the complete set of isomers. All ten isomers were tested for their antifeedant effect on the pine weevil. The effect varied considerably among the hydroxy-methoxybenzoic esters. Methyl 2-hydroxy-3-methoxybenzoate showed the highest effect and may thus be a candidate for practical use in pine weevil pest management.